Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1.

Peacock JW, Takeuchi A, Hayashi N, Liu L, Tam KJ, Al Nakouzi N, Khazamipour N, Tombe T, Dejima T, Lee KC, Shiota M, Thaper D, Lee WC, Hui DH, Kuruma H, Ivanova L, Yenki P, Jiao IZ, Khosravi S, Mui AL, Fazli L, Zoubeidi A, Daugaard M, Gleave ME, Ong CJ.

EMBO Mol Med. 2018 Feb;10(2):219-238. doi: 10.15252/emmm.201707689.

2.

The effects of opposite-directional static contraction of the muscles of the right upper extremity on the ipsilateral right soleus H-reflex.

Shiratani T, Arai M, Kuruma H, Masumoto K.

J Bodyw Mov Ther. 2017 Jul;21(3):528-533. doi: 10.1016/j.jbmt.2016.08.004. Epub 2016 Aug 12.

PMID:
28750960
3.

Prospective comparison of the efficacy of caudal versus periprostatic nerve block, both with intrarectal local anesthesia, during transrectal ultrasonography-guided prostatic needle biopsy.

Urabe F, Kimura T, Shimomura T, Onuma H, Yamamoto T, Sasaki H, Miki J, Kuruma H, Miki K, Egawa S.

Scand J Urol. 2017 Aug;51(4):245-250. doi: 10.1080/21681805.2017.1318299. Epub 2017 Apr 26.

PMID:
28443752
4.

[EXPRESSION OF PLAKIN FAMILY IN UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT].

Hasegawa Y, Kamata Y, Yorozu T, Takahashi H, Kimura T, Kuruma H, Tabata R, Shimomura T, Yamada H, Sasaki H, Egawa S.

Nihon Hinyokika Gakkai Zasshi. 2017;108(2):87-95. doi: 10.5980/jpnjurol.108.87. Japanese.

5.

The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.

Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, Jama R, Nip KM, Angeles A, Johnson F, Wyatt AW, Fazli L, Gleave ME, Lin D, Rubin MA, Collins CC, Wang Y, Beltran H, Zoubeidi A.

Cancer Discov. 2017 Jan;7(1):54-71. doi: 10.1158/2159-8290.CD-15-1263. Epub 2016 Oct 26.

6.

Do androgen deprivation and the biologically equivalent dose matter in low-dose-rate brachytherapy for intermediate-risk prostate cancer?

Tabata R, Kimura T, Kuruma H, Sasaki H, Kido M, Miki K, Takahashi H, Aoki M, Egawa S.

Cancer Med. 2016 Sep;5(9):2314-22. doi: 10.1002/cam4.820. Epub 2016 Jul 25.

7.

Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7.

Shiota M, Fujimoto N, Imada K, Yokomizo A, Itsumi M, Takeuchi A, Kuruma H, Inokuchi J, Tatsugami K, Uchiumi T, Oda Y, Naito S.

J Natl Cancer Inst. 2016 Feb 8;108(7). doi: 10.1093/jnci/djw005. Print 2016 Jul.

PMID:
26857528
8.

Time Trends in Histological Features of Latent Prostate Cancer in Japan.

Kimura T, Takahashi H, Okayasu M, Kido M, Inaba H, Kuruma H, Yamamoto T, Furusato B, Furusato M, Wada T, Egawa S.

J Urol. 2016 May;195(5):1415-1420. doi: 10.1016/j.juro.2015.11.068. Epub 2015 Dec 8.

PMID:
26678955
9.

Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.

Shiota M, Itsumi M, Takeuchi A, Imada K, Yokomizo A, Kuruma H, Inokuchi J, Tatsugami K, Uchiumi T, Oda Y, Naito S.

Endocr Relat Cancer. 2015 Dec;22(6):889-900. doi: 10.1530/ERC-15-0225. Epub 2015 Aug 26.

PMID:
26311513
10.

Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.

Shiota M, Bishop JL, Takeuchi A, Nip KM, Cordonnier T, Beraldi E, Kuruma H, Gleave ME, Zoubeidi A.

Oncotarget. 2015 Apr 20;6(11):9086-98.

11.

Loss of periplakin expression is associated with pathological stage and cancer-specific survival in patients with urothelial carcinoma of the urinary bladder.

Matsumoto K, Ikeda M, Sato Y, Kuruma H, Kamata Y, Nishimori T, Tomonaga T, Nomura F, Egawa S, Iwamura M.

Biomed Res. 2014;35(3):201-6.

12.

Pulmonary metastases after low-dose-rate brachytherapy for localized prostate cancer.

Kido M, Kuruma H, Sasaki H, Miki K, Aoki M, Kimura T, Takahash H, Kanehira C, Egawa S.

Korean J Urol. 2014 May;55(5):309-14. doi: 10.4111/kju.2014.55.5.309. Epub 2014 May 12.

13.

Salvage partial brachytherapy for prostate cancer recurrence after primary brachytherapy.

Sasaki H, Kido M, Miki K, Kuruma H, Takahashi H, Aoki M, Egawa S.

Int J Urol. 2014 Jun;21(6):572-7. doi: 10.1111/iju.12373. Epub 2013 Dec 23.

14.

Mid-term outcome of permanent prostate iodine-125 brachytherapy in Japanese patients.

Kimura T, Kido M, Miki K, Yamamoto T, Sasaki H, Kuruma H, Hayashi N, Takahashi H, Aoki M, Egawa S.

Int J Urol. 2014 May;21(5):473-8. doi: 10.1111/iju.12347. Epub 2013 Nov 20.

15.

Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability.

Matsumoto H, Yamamoto Y, Shiota M, Kuruma H, Beraldi E, Matsuyama H, Zoubeidi A, Gleave M.

Cancer Res. 2013 Aug 15;73(16):5206-17. doi: 10.1158/0008-5472.CAN-13-0359. Epub 2013 Jun 20.

16.

Castration-resistant prostate cancer: novel therapeutics pre- or post- taxane administration.

Shiota M, Yokomizo A, Fujimoto N, Kuruma H, Naito S.

Curr Cancer Drug Targets. 2013 May;13(4):444-59. Review.

PMID:
23517595
17.

A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.

Kuruma H, Matsumoto H, Shiota M, Bishop J, Lamoureux F, Thomas C, Briere D, Los G, Gleave M, Fanjul A, Zoubeidi A.

Mol Cancer Ther. 2013 May;12(5):567-76. doi: 10.1158/1535-7163.MCT-12-0798. Epub 2013 Mar 14.

18.

Words of Wisdom: re: international variation in prostate cancer incidence and mortality rates.

Kuruma H, Egawa S.

Eur Urol. 2013 Mar;63(3):583-4. doi: 10.1016/j.eururo.2012.12.012. No abstract available.

PMID:
23357896
19.

[Solitary adrenal metastasis of bladder carcinoma : a case report].

Honda M, Suzuki K, Sugaya S, Kuruma H, Abe M, Koshitaka Y, Hasegawa Y, Kondo N, Egawa S.

Hinyokika Kiyo. 2012 Sep;58(9):495-7. Japanese.

20.

[New biomarkers for the prostate cancer].

Ishii G, Kimura T, Kuruma H, Egawa S.

Nihon Rinsho. 2012 May;70(5):828-32. Review. Japanese.

PMID:
22620008
21.

[New marker proteins for prostate cancer].

Hayashi N, Kuruma H, Egawa S.

Nihon Rinsho. 2011 Jun;69 Suppl 5:140-4. Review. Japanese. No abstract available.

PMID:
22207959
22.

Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.

Guo C, Linton A, Kephart S, Ornelas M, Pairish M, Gonzalez J, Greasley S, Nagata A, Burke BJ, Edwards M, Hosea N, Kang P, Hu W, Engebretsen J, Briere D, Shi M, Gukasyan H, Richardson P, Dack K, Underwood T, Johnson P, Morell A, Felstead R, Kuruma H, Matsimoto H, Zoubeidi A, Gleave M, Los G, Fanjul AN.

J Med Chem. 2011 Nov 10;54(21):7693-704. doi: 10.1021/jm201059s. Epub 2011 Oct 7.

PMID:
21936524
23.

Neural activation during imitation of movements presented from four different perspectives: a functional magnetic resonance imaging study.

Watanabe R, Watanabe S, Kuruma H, Murakami Y, Seno A, Matsuda T.

Neurosci Lett. 2011 Oct 3;503(2):100-4. doi: 10.1016/j.neulet.2011.08.016. Epub 2011 Aug 17.

PMID:
21871533
24.

Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.

Lamoureux F, Thomas C, Yin MJ, Kuruma H, Beraldi E, Fazli L, Zoubeidi A, Gleave ME.

Cancer Res. 2011 Sep 1;71(17):5838-49. doi: 10.1158/0008-5472.CAN-11-0994. Epub 2011 Jul 7.

25.

T2 mapping of muscle activity using ultrafast imaging.

Tawara N, Nitta O, Kuruma H, Niitsu M, Itoh A.

Magn Reson Med Sci. 2011;10(2):85-91.

26.

A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis.

Lamoureux F, Thomas C, Yin MJ, Kuruma H, Fazli L, Gleave ME, Zoubeidi A.

Clin Cancer Res. 2011 Apr 15;17(8):2301-13. doi: 10.1158/1078-0432.CCR-10-3077. Epub 2011 Feb 24. Erratum in: Clin Cancer Res. 2011 Jul 15;17(14):4916.

27.

Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo.

Thomas C, Zoubeidi A, Kuruma H, Fazli L, Lamoureux F, Beraldi E, Monia BP, MacLeod AR, Thüroff JW, Gleave ME.

Mol Cancer Ther. 2011 Feb;10(2):347-59. doi: 10.1158/1535-7163.MCT-10-0850. Epub 2011 Jan 7.

28.

Dietary administration of mushroom mycelium extracts in patients with early stage prostate cancers managed expectantly: a phase II study.

Sumiyoshi Y, Hashine K, Kakehi Y, Yoshimura K, Satou T, Kuruma H, Namiki S, Shinohara N.

Jpn J Clin Oncol. 2010 Oct;40(10):967-72. doi: 10.1093/jjco/hyq081. Epub 2010 Jun 3.

PMID:
20522448
29.

Replication of prostate cancer risk loci in a Japanese case-control association study.

Yamada H, Penney KL, Takahashi H, Katoh T, Yamano Y, Yamakado M, Kimura T, Kuruma H, Kamata Y, Egawa S, Freedman ML.

J Natl Cancer Inst. 2009 Oct 7;101(19):1330-6. doi: 10.1093/jnci/djp287. Epub 2009 Sep 2.

PMID:
19726753
30.

Patterns of failure and influence of potential prognostic factors after surgery in transitional cell carcinoma of the upper urinary tract.

Shimomura T, Ohtsuka N, Yamada H, Miki J, Hayashi N, Kimura T, Kuruma H, Egawa S.

Int J Clin Oncol. 2009 Jun;14(3):213-8. doi: 10.1007/s10147-008-0837-4. Epub 2009 Jul 11.

PMID:
19593612
31.

Functional T(2) mapping of the trunkal muscle.

Tawara N, Nitta O, Kuruma H, Niitsu M, Hoshikawa A, Okuwaki T, Itoh A.

Magn Reson Med Sci. 2009;8(2):81-3. No abstract available.

32.

Staphylococcal nuclease domain-containing protein 1 as a potential tissue marker for prostate cancer.

Kuruma H, Kamata Y, Takahashi H, Igarashi K, Kimura T, Miki K, Miki J, Sasaki H, Hayashi N, Egawa S.

Am J Pathol. 2009 Jun;174(6):2044-50. doi: 10.2353/ajpath.2009.080776. Epub 2009 May 12.

33.

The maximum tumour length in biopsy cores as a predictor of outcome after radical prostatectomy.

Hayashi N, Urashima M, Kuruma H, Arai Y, Kuwao S, Iwamura M, Egawa S.

BJU Int. 2008 Jan;101(2):175-80. Epub 2007 Sep 10.

34.

Computer simulated additional deep apical biopsy enhances cancer detection in palpably benign prostate gland.

Matsumoto K, Egawa S, Satoh T, Kuruma H, Yanagisawa N, Baba S.

Int J Urol. 2006 Oct;13(10):1290-5.

35.

Prostate-specific antigen adjusted for total prostatic tumor volume as a predictor for outcome after radical prostatectomy.

Hayashi N, Urashima M, Ikemoto I, Kuruma H, Arai Y, Kuwao S, Baba S, Egawa S.

Prostate Cancer Prostatic Dis. 2007;10(1):60-5. Epub 2006 Oct 3.

PMID:
17003775
36.

Ammonium acid urate urolithiasis in Japan.

Kuruma H, Arakawa T, Kubo S, Hyodo T, Matsumoto K, Satoh T, Egawa S, Baba S.

Int J Urol. 2006 May;13(5):498-501.

37.

Search for biomarkers of aggressiveness in bladder cancer.

Egawa S, Kuruma H.

Eur Urol. 2006 Jul;50(1):20-2. Epub 2006 Feb 28. No abstract available.

PMID:
16530926
38.

Occupational bladder cancer: from cohort study to biologic molecular marker.

Matsumoto K, Irie A, Satoh T, Kuruma H, Arakawa T, Baba S.

Med Sci Monit. 2005 Oct;11(10):RA311-5. Epub 2005 Sep 26. Review.

PMID:
16192913
39.

Growth inhibition efficacy of an adenovirus expressing dual therapeutic genes, wild-type p53, and anti-erbB2 ribozyme, against human bladder cancer cells.

Irie A, Matsumoto K, Anderegg B, Kuruma H, Kashani-Sabet M, Scanlon KJ, Uchida T, Baba S.

Cancer Gene Ther. 2006 Mar;13(3):298-305.

PMID:
16110311
40.

High molecular mass proteome of androgen-independent prostate cancer.

Kuruma H, Egawa S, Oh-Ishi M, Kodera Y, Satoh M, Chen W, Okusa H, Matsumoto K, Maeda T, Baba S.

Proteomics. 2005 Mar;5(4):1097-112.

PMID:
15712236
41.

Proteome analysis of prostate cancer.

Kuruma H, Egawa S, Oh-Ishi M, Kodera Y, Maeda T.

Prostate Cancer Prostatic Dis. 2005;8(1):14-21. Review.

PMID:
15477873
42.

Weekly paclitaxel plus estramustine combination therapy in hormone-refractory prostate cancer: a pilot study.

Kuruma H, Fujita T, Shitara T, Egawa S, Yokoyama E, Baba S.

Int J Urol. 2003 Sep;10(9):470-5.

43.

Delayed recovery of urinary continence after laparoscopic radical prostatectomy.

Egawa S, Kuruma H, Suyama K, Iwamura M, Baba S.

Int J Urol. 2003 Apr;10(4):207-12.

44.

[Prostate-specific antigen and its related parameters in detecting prostate cancer].

Kuruma H, Egawa S.

Gan To Kagaku Ryoho. 2003 Jan;30(1):11-5. Japanese.

PMID:
12557698
45.

[Subsequent upper urothelial cancer following bladder tumor].

Kuruma H, Ao T, Murayama M, Mizoguchi H, Koshiba K.

Hinyokika Kiyo. 2002 Apr;48(4):199-202. Japanese.

46.

[A case of gastrointestinal stromal tumor of rectum, difficult to differentiate from leiomyosarcoma of prostate].

Kuruma H, Ao T, Suyama K, Okuno N, Mizoguchi H, Murayama M, Koshiba K, Motoori T.

Nihon Hinyokika Gakkai Zasshi. 2001 Sep;92(6):624-7. Japanese.

47.

[Intraperitoneal dissemination of testicular tumor: a case report].

Kuruma H, Ikeda Y, Nakajima F, Miyajima A, Asano T, Hayakawa M, Nakamura H.

Hinyokika Kiyo. 1998 Jun;44(6):423-5. Japanese.

48.

T2*-weighted dynamic MR imaging in renal artery or vein stenosis.

Tsushima Y, Murakami T, Kuruma H, Kondo T, Kusano S.

AJR Am J Roentgenol. 1997 Apr;168(4):1041-3. No abstract available.

PMID:
9124111

Supplemental Content

Loading ...
Support Center